Nabriva Therapeutics AG (NASDAQ:NBRV) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday.

According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “

A number of other brokerages have also weighed in on NBRV. HC Wainwright began coverage on Nabriva Therapeutics AG in a research note on Thursday, September 8th. They set a “buy” rating and a $16.00 price objective on the stock. Wedbush restated an “outperform” rating and set a $17.00 price objective on shares of Nabriva Therapeutics AG in a research note on Tuesday, August 9th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. Nabriva Therapeutics AG has an average rating of “Buy” and an average target price of $15.89.

Analyst Recommendations for Nabriva Therapeutics AG (NASDAQ:NBRV)

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Nabriva Therapeutics AG (NASDAQ:NBRV) opened at 6.94 on Wednesday. The firm’s market cap is $147.52 million. The stock’s 50 day moving average price is $7.47 and its 200 day moving average price is $7.88. Nabriva Therapeutics AG has a 52 week low of $6.61 and a 52 week high of $10.69.

Nabriva Therapeutics AG (NASDAQ:NBRV) last announced its earnings results on Tuesday, August 9th. The company reported ($0.50) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($6.25) by $5.75. On average, equities research analysts predict that Nabriva Therapeutics AG will post ($1.93) EPS for the current year.

Several institutional investors have recently modified their holdings of NBRV. Jackson Park Capital LLC acquired a new position in shares of Nabriva Therapeutics AG during the second quarter valued at about $195,000. Opaleye Management Inc. raised its position in shares of Nabriva Therapeutics AG by 24.5% in the first quarter. Opaleye Management Inc. now owns 273,800 shares of the company’s stock valued at $2,453,000 after buying an additional 53,800 shares during the last quarter. Finally, Vivo Capital LLC acquired a new position in shares of Nabriva Therapeutics AG during the first quarter valued at about $28,239,000. Institutional investors own 63.05% of the company’s stock.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs).

5 Day Chart for NASDAQ:NBRV

Get a free copy of the Zacks research report on Nabriva Therapeutics AG (NBRV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with's FREE daily email newsletter.